Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
Subscribe To Our Newsletter & Stay Updated
